Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).

NCT06567015 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT06567015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06567015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II First-In-Human Open-label Trial to Assess Safety and Efficacy of STX-241 in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Resistant to EGFR Tyrosine Kinase Inhibitors (TKIs).
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 17, 2024
Completion date
July 31, 2030
Enrollment
171 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)